Pcn240 - All-Comers vs. Biomarker Based Patient Selection for Biotherapies in Oncology: Impact on Drug Development and Market Access

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.322
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Drug Repurposing in Pharmaceutical Industry and Its Impact on Market Access: Market Access Implications

Journal of Market Access & Health Policy
2014English

Biomarkers in Oncology Drug Development

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2008English

Market Access Advancements and Challenges in “Drug-Companion Diagnostic Test” Co-Development in Europe

Journal of Personalized Medicine
Medicine
2015English

PHP16 Generic Drug Market Access in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Pmd168 - Market Access for Companion Diagnostics in Oncology in the Eu5 and Asia-Pacific Region

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Patient Preparation, Vascular Access, and Guiding Catheter Selection

2018English

Impact of Introducing Costs/Qaly Threshold on Access to Oncology Medicines in Slovakia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Access All Ages: Assessing the Impact of Age on Access to Surgical Treatment

The Bulletin of the Royal College of Surgeons of England
2012English

Clinician Participation in CADTH’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations

Current Oncology
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy